Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/15/2024 | Neutral → Sell | BTIG Research | |
5/10/2024 | Mkt Perform → Underperform | William Blair | |
11/14/2023 | $3.50 → $2.50 | Outperform → Mkt Perform | Raymond James |
11/9/2023 | Buy → Neutral | BTIG Research | |
6/2/2023 | $3.00 → $1.25 | Neutral → Sell | Goldman |
5/11/2023 | Outperform → Mkt Perform | William Blair | |
11/29/2022 | $6.00 | Buy | Berenberg |
10/4/2022 | $5.00 | Equal-Weight | Morgan Stanley |
Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com.
BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced the completion of the first milestone of a previously announced partnership with Merck, known as MSD outside of the United States and Canada, focused on improving biologic manufacturing. As part of this milestone completion, Ginkgo will receive a research milestone payment of $9 million in cash. The two companies will now move on to the second stage of this partnership, which will be focused on continuing to improve the
Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON, Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investor
10-Q - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)
25-NSE - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs new and expanded deals with Novo Nordisk and achieves a major research milestone with Merck BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September 30, 2024. The update, including a webcast slide presentation with additional details on the third quarter and supplemental financial information will be available at investors.ginkgobioworks.com.
Presentation and Q&A session scheduled for post-market on Tuesday, November 12, 2024 BOSTON, Nov. 5, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the third quarter ended September 30, 2024, on Tuesday, November 12, 2024, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investor
Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force BOSTON, Aug. 8, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", ))), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2024. The update, including a webcast slide presentation with additional details on the second quarter and supplemental financial information, will be available at investors.ginkgobioworks.com. Second Qu
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
3 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)
BTIG Research downgraded Ginkgo Bioworks from Neutral to Sell
William Blair downgraded Ginkgo Bioworks from Mkt Perform to Underperform
Raymond James downgraded Ginkgo Bioworks from Outperform to Mkt Perform and set a new price target of $2.50 from $3.50 previously
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)
On Wednesday, Cathie Wood-led Ark Invest made a notable move by offloading a significant number of shares in Tesla Inc (NASDAQ:TSLA), despite the recent rally driven by the company’s impressive second-quarter delivery numbers. The Tesla Trade Ark Invest reduced its stake in Tesla across its ARK Innovation ETF (NYSE:ARKK), selling 13,213 shares. This transaction came as a surprise, given that Tesla’s shares had recently soared 10.20% on Tuesday, marking the best intraday session since late April. Notably, on Tuesday, Ark Invest sold Tesla shares worth $14.5 million. The boost was primarily driven by the Elon Musk-led company’s second-quarter performance. Tesla reported 443,956 delive
On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN), amidst a volatile market. These prominent trades were part of a series of transactions carried out by Ark’s various ETFs. The ROKU Trade ARK Innovation ETF (NYSE:ARKK) and ARK Next Generation Internet ETF (NYSE:ARKW) bought 127,540 shares in Roku Inc. The ARKK fund acquired 106,420 shares, while the ARKW fund added 21,120 shares. The transaction amounted to $7.3 million. On Wednesday, Roku shares closed 4.6% higher at $57.16 in the regular session. Notably, Wood’s firm purchased $5.3 million worth of Roku shares a day earlier. These moves come amidst Roku
Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON, May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.
Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network. The Ginkgo Technology Netw
The companies plan to join forces to set up pathogen monitoring programs utilizing Illumina technology across Concentric's global network BOSTON and SAN DIEGO, Jan. 15, 2024 /PRNewswire/ -- Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that it has entered into a Co-Marketing Agreement with Illumina, Inc. (NASDAQ:ILMN), a global leader in DNA sequencing and array-based technologies, to partner on expanding biosecurity capabilities globally.